Research Analysts Offer Predictions for Vericel Q2 Earnings

Vericel Co. (NASDAQ:VCEL - Free Report) - Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Vericel in a research report issued on Thursday, February 27th. Leerink Partnrs analyst M. Kratky now anticipates that the biotechnology company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.01. The consensus estimate for Vericel's current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel's Q3 2025 earnings at $0.03 EPS, FY2026 earnings at $0.71 EPS, FY2027 earnings at $1.28 EPS and FY2029 earnings at $2.74 EPS.

A number of other equities research analysts also recently issued reports on the stock. Truist Financial reiterated a "buy" rating and set a $61.00 price target (down from $67.00) on shares of Vericel in a research report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Canaccord Genuity Group upped their target price on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a report on Monday, February 3rd. BTIG Research raised their price target on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Finally, Stephens reiterated an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.29.

Remove Ads

Vericel Stock Down 5.4 %

Shares of NASDAQ VCEL traded down $2.77 during midday trading on Monday, hitting $48.76. The company had a trading volume of 315,355 shares, compared to its average volume of 418,659. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 812.80 and a beta of 1.72. Vericel has a twelve month low of $39.12 and a twelve month high of $63.00. The business has a 50-day simple moving average of $56.63 and a two-hundred day simple moving average of $51.91.

Insider Activity at Vericel

In other Vericel news, insider Jonathan Siegal sold 3,908 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. This represents a 76.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,500 shares of company stock valued at $466,200 over the last quarter. Insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Vericel

Several hedge funds have recently made changes to their positions in VCEL. FMR LLC lifted its position in Vericel by 1.0% during the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company's stock worth $100,251,000 after buying an additional 22,461 shares during the period. Congress Asset Management Co. lifted its holdings in shares of Vericel by 12.6% during the 4th quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock worth $79,847,000 after acquiring an additional 162,419 shares during the period. Wellington Management Group LLP boosted its position in shares of Vericel by 119.3% in the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after acquiring an additional 701,064 shares during the last quarter. GW&K Investment Management LLC boosted its position in shares of Vericel by 2.4% in the fourth quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company's stock worth $69,953,000 after acquiring an additional 30,180 shares during the last quarter. Finally, William Blair Investment Management LLC grew its holdings in Vericel by 66.3% in the fourth quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock valued at $69,100,000 after purchasing an additional 501,736 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.